清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial

医学 曲美替尼 吉西他滨 临床终点 肿瘤科 内科学 彭布罗利珠单抗 胰腺癌 放射治疗 临床试验 癌症 免疫疗法 MAPK/ERK通路 生物 细胞生物学 激酶
作者
Xiaofei Zhu,Wenyu Liu,Yangsen Cao,Xingzhu Ju,Xianzhi Zhao,Lingong Jiang,Yusheng Ye,Huojun Zhang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:55: 101764-101764 被引量:2
标识
DOI:10.1016/j.eclinm.2022.101764
摘要

There are a lack of studies about whether radiation dose escalation synergizes with immunotherapy and targeted therapy in pancreatic cancer. In this study, we performed a secondary analysis to investigate whether a high radiation dose rather than a low dose plus pembrolizumab and trametinib provided improved survival compared with gemcitabine in post-operative locally recurrent pancreatic cancer.In this open-label, randomised, controlled, phase 2 trial, eligible patients with pancreatic ductal adenocarcinoma characterized by mutant KRAS and positive immunohistochemical staining of PD-L1 and documented post-operative local recurrence were randomly assigned using an interactive voice or web response system, without stratification, to receive stereotactic body radiation therapy (SBRT) with doses ranging from 35 to 40Gy in five fractions, pembrolizumab 200 mg every three weeks and oral trametinib 2 mg once daily (SBRT + K + M) or SBRT and gemcitabine (1000 mg/m2) on day 1 and 8 of each 21-day cycle (SBRT + G) until disease progression in our hospital in China. Those had radiotherapy, immunotherapy or targeted therapy were excluded. Patients and investigators were not masked to the assignment. In each arm, patients were stratified based on biologically effective dose (BED10; α/β = 10) of 60-65Gy and BED10 ≥65Gy. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). All patients received their assigned treatment and were included in the efficacy and safety analyses. This study is registered with ClinicalTrials.gov, NCT02704156.Between Oct 10, 2016, and Oct 28, 2017, 147 of 170 randomly assigned participants were eligible for inclusion in this analysis. In BED10 of 60-65Gy group, 34 and 29 patients had SBRT + G and SBRT + K + M, respectively. While there were 42 and 42 patients with SBRT + G and SBRT + K + M in BED10 ≥65Gy group. Patients in the SBRT + K + M group had longer OS compared with the SBRT + G group, but this did not reach statistical significance (median: 15.1 vs. 12.4 months, HR 0.67 [95%CI 0.43-1.04]; p = 0.071). For BED10 of 60-65Gy, OS was similar between patients in the SBRT + K + M and SBRT + G groups (median, 13.6 vs. 12.4 months; HR 0.69 [95% CI 0.41-1.16]; p = 0.16). For BED10 of ≥65Gy, PFS was prolonged with SBRT + K + M versus SBRT + G (median: 8.6 vs. 5.0 months, HR 0.48 [95% CI 0.31-0.77]; p = 0.0021). For BED10 of 60-65Gy, there was no significant difference in PFS between the two groups (PFS: median, 7.9 vs. 4.3 months; HR 0.69 [95% CI 0.42-1.15]; p = 0.16). In BED10 of 60-65Gy group, 7 (20.6%) and 8 patients (27.6%) with SBRT + G and SBRT + K + M had grade 3 or 4 adverse events (p = 0.52). In BED10 ≥65Gy group, 8 (19.0%) and 12 patients (28.6%) with SBRT + G and SBRT + K + M had grade 3 or 4 adverse events (p = 0.31). No treatment-related death occurred.Dose escalation of SBRT may improve PFS with pembrolizumab and trametnib versus gemcitabine for patients with post-operative locally recurrent pancreatic cancer. However, benefits of PFS did not translate into longer OS. This may be ascribed to small sample size and post-hoc analysis that was not powered to determine the significance. Therefore, synergy of high dose of SBRT with immunotherapy and targeted therapy required further investigations in phase 3 trials.Shanghai Shenkang Centre and Changhai Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
ww完成签到,获得积分10
19秒前
斯文败类应助ceeray23采纳,获得20
28秒前
机智秋莲发布了新的文献求助20
30秒前
ChatGPT完成签到,获得积分10
38秒前
所所应助科研通管家采纳,获得10
46秒前
46秒前
54秒前
ceeray23发布了新的文献求助20
59秒前
海阔天空完成签到 ,获得积分10
1分钟前
zys发布了新的文献求助10
1分钟前
ffdhdh应助LYZSh采纳,获得10
1分钟前
2分钟前
机智秋莲完成签到,获得积分20
2分钟前
欣欣子完成签到 ,获得积分10
2分钟前
apt完成签到 ,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
3分钟前
董可以发布了新的文献求助10
3分钟前
Orange应助董可以采纳,获得10
3分钟前
飞翔的企鹅完成签到,获得积分10
4分钟前
4分钟前
董可以发布了新的文献求助10
4分钟前
LYZSh发布了新的文献求助10
4分钟前
彭于晏应助董可以采纳,获得10
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
LYZSh完成签到,获得积分10
4分钟前
鳗鱼飞松完成签到 ,获得积分20
4分钟前
widesky777完成签到 ,获得积分0
4分钟前
霜二完成签到 ,获得积分10
5分钟前
xiaofeixia完成签到 ,获得积分10
5分钟前
ys完成签到 ,获得积分10
6分钟前
grace完成签到,获得积分10
6分钟前
ll完成签到,获得积分20
6分钟前
852应助ll采纳,获得10
6分钟前
mojito完成签到 ,获得积分10
6分钟前
muriel完成签到,获得积分10
6分钟前
科研通AI2S应助科研通管家采纳,获得10
6分钟前
奥利奥利奥完成签到 ,获得积分10
7分钟前
7分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990543
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234